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Abstract
Objective—To determine whether consumption of whole-grain; rye bread, oatmeal, and whole-
wheat bread, during different periods of life, is associated with risk of prostate cancer (PCa).
Methods—In 2002 to 2006, 2,268 men, aged 67-96 years, reported their dietary habits in the
AGES-Reykjavik cohort study. Dietary habits were assessed for early-, mid- , and current life
using a validated food frequency questionnaire (FFQ). Through linkage to cancer- and mortality
registers, we retrieved information on PCa diagnosis and mortality through 2009. We used
regression models to estimate odds ratios (ORs) and hazard ratios (HRs) for PCa according to
whole grain consumption, adjusted for possible confounding factors including fish-, fish liver oil-,
meat-, and milk intake.
Results—Of the 2,268 men, 347 had or were diagnosed with PCa during follow-up, 63 with
advanced disease (stage 3+ or died of PCa). Daily rye bread consumption in adolescence (vs. less
than daily) was associated with a decreased risk of PCa diagnosis (OR = 0.76, 95% Confidence
interval (CI): 0.59-0.98), and of advanced PCa (OR = 0.47, 95% CI: 0.27-0.84). High intake of
oatmeal in adolescence (≥5 vs. ≤4 times/ week) was not significantly associated with risk of PCa
diagnosis (OR = 0.99, 95% CI: 0.77-1.27) nor advanced PCa (OR = 0.67, 95% CI: 0.37-1.20).
Mid-, and late life consumption of rye bread, oatmeal, or whole-wheat bread was not associated
with PCa risk.
Conclusion—Our results suggest that rye bread consumption in adolescence may be associated
with reduced risk of PCa, particularly advanced disease.
Correspondence to: Johanna Eyrun Torfadottir, Centre of Public Health Sciences, University of Iceland. Stapi v/Hringbraut, 101
Reykjavik, Iceland. Telephone: (+354) 699 2405; Fax (+354) 562 2013; jet1@hi.is.
Conflict of interest: None declared
NIH Public Access
Author Manuscript
Cancer Causes Control. Author manuscript; available in PMC 2013 February 11.
Published in final edited form as:
Cancer Causes Control. 2012 June ; 23(6): 941–950. doi:10.1007/s10552-012-9965-2.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Keywords
adolescent; diet; epidemiology; rye bread; prostatic neoplasms; whole-grain; AGES Reykjavik
study
INTRODUCTION
Several lines of evidence support a role of dietary factors in prostate cancer incidence and
mortality. Firstly, prostate cancer is the malignancy with the largest variation in incidence
and mortality across countries, a finding that cannot be completely accounted for by
screening patterns [1]. Moreover, the rapid change in prostate cancer incidence and
mortality among second generation immigrants to Western countries compared with host
countries suggests a role of modifiable risk factors in early life, such as dietary habits [2].
The identification of dietary factors that lower risk of prostate cancer incidence and
progression could have a major public health impact.
Whole-grain has been linked to reduced cancer risk. Although mechanisms behind it are as
yet unclear, many components of the whole grain could play a role such as fiber, starch,
fatty acids, antioxidants, minerals, vitamins, phytoestrogens (lignans) and phenolic
compounds [3]. Beneficial effects of whole-grain consumption for hormonal-dependent
cancer such as prostate cancer could for example be due to lignans that affect the steroid
metabolism [4]. In addition, dietary fiber increases butyrate production in the colon, and
butyrate has been shown to inhibit cell growth, and promote cell differentiation and
apoptosis in prostate cancer cells [5]. Rye, a rich source of lignans, minerals and vitamins
[4], has also been suggested to have positive effects on long-term insulin secretion [6,7],
which could be important since prostate cancer has been associated with insulin resistance
[8-10]
Few epidemiological studies have specifically studied intake of whole-grain and prostate
cancer risk, but two studies have reported increased risk [11,12] and three studies found no
association [13-15]. These studies did not present data on advanced and localized prostate
cancer separately. However, one recent prospective study on whole-grain rye-, and oatmeal
consumption, among Danish men in their fifties and sixties at baseline, found no association
between whole grain consumption and either localized or advanced prostate cancer [16].
Yet, animal models indicate that rye bran may have protective properties against prostate
cancer [17-19] and pilot intervention studies among prostate cancer patients have shown
promising effects of high rye intake on markers of prostate cancer progression [20,21]. No
published study to date has addressed rye intake in early life or other types of whole grain
and prostate cancer risk. Early life diet may be important in the pathogenesis of prostate
cancer, because the prostate undergoes considerable growth and maturation during pubertal
development. We have previously found that frequent milk intake in adolescence as well as
rural residency in early life, representing high milk intake, was associated with increased
risk of advanced prostate cancer [22], which suggests a role of modifiable risk factors in
early life.
In Iceland, rye and oatmeal were the main types of whole-grain in the diet during the first
half of the 20th century. In particular, rye consumption was 152 kilograms per year on
average for an adult male in 1930 [23]. However there was considerable residency-based
variability in dietary habits, including rye bread consumption, which was most common in
rural areas and substantially lower in other areas during this time period [24].
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In this study we investigated whether whole-grain consumption in different periods of life is
associated with risk of prostate cancer in adult life in a prospective cohort study.
METHODS
Study population
The Reykjavík Study, established in 1967, is a population-based cohort of men aged 33 to
79 years, residing in the Reykjavik capital area at enrolment (1967-1987). A subgroup of
2,424 men was later enrolled in the AGES-Reykjavik study, initiated in 2002 [25].
Dietary habits in early-, mid-, and late-life
In total 2,268 men participated in AGES-Reykjavik, including men with prevalent prostate
cancer (n = 214) and provided information on dietary habits in early life (between the ages
of 14 to 19), midlife (between the ages of 40-50) and at the present time using a short,
validated food frequency questionnaire (FFQ) [26]. The FFQ provides information on
frequency of intake of eleven common foods and food groups, including rye bread and
flatbread made of rye (hereafter referred to as rye bread) and oatmeal. The question on
oatmeal consumption in the midlife and current period also included muesli. For these items,
along with nine other food groups, participants reported frequency of consumption in each
time period, using the following response categories; 1) never, 2) less than once a week, 3)
1-2/ week, 4) 3-4/ week, 5) 5-6/ week, 6) daily, and 7) more than once a day. These other
food groups were: meat, fish (including salted or smoked fish), blood sausage or liver
sausage, potatoes, fruits, vegetables, milk and milk products, whole wheat bread (only in
midlife and at present time), and fish liver oil. The current analysis is based on those men
responding to questions on early life rye bread consumption (n = 2,258), midlife rye bread
consumption (n = 2,260), early life oatmeal consumption (n = 2,255), midlife oatmeal
consumption (n = 2,259) and midlife whole wheat bread consumption (n =2,255). Analysis
on current intake were based on participants, who were free of prostate cancer where 1,978
men answered question on rye bread, 1,983 on oatmeal and 1,980 on whole-wheat bread.
Covariate Assessment
Information on potential confounders in midlife was retrieved from the questionnaire or
health check-ups at entry to the Reykjavik Study. We collected information on birth year,
age at entry to the study, family history of prostate disease (yes/no), early life residency
(rural, city, seaside village) [22], whether participants went regularly to a physician for a
health check-up (at least every 3rd year) and education (elementary school, secondary
school, college education, and university education). Information on nutritional factors such
as fish-, salted or smoked fish, fish liver oil-, meat- and milk intake for all time periods were
obtained from the FFQ in the AGES-Reykjavik study as well as recall information about
physical activity in the past [27].
Body Mass Index (BMI, kg/m2) was calculated from weight and height measured at the
clinical exam at enrollment, categorized by obesity status (≥ 30 or <30 kg/m2). Participants
were considered to have type 2 diabetes if they had a self-reported history or if they had
fasting blood glucose of ≥126 mg/dL at enrolment [28].
Ascertainment of outcome
We ascertained prostate cancer diagnoses through linkage with the nationwide Icelandic
Cancer Registry, which captures 99% of cancers diagnosed in Iceland [29-31]. All men with
prevalent prostate cancer at entry to the cohort (n=214) or diagnosed at follow-up, through
Dec 31 2009 (n = 133) were included in the analysis. Information on cause of death was
obtained from Statistics Iceland. Classification of stage at diagnosis was based on medical
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records and classified as stage I (incidental finding) included T1a, NX/0, and MX/0. Stage II
(tumor confined to prostate gland) included T1b/1c/1/2, NX/0, and MX/0. Stage III (tumor
extending through prostatic capsule) included T3, NX/0, and MX/0. Stage IV (locally
advanced or metastatic disease) included T4, NX/0, MX/0; or any T, N1 and/or M1.We had
information on stage at diagnosis for approximately 75% of cases. Information on Gleason
grade was not available for this study. Since 1990 there has been a rapid increase in prostate
cancer incidence rates in Iceland, but at the same time the mortality rates have stayed
similar, suggesting increased detection of nonlethal tumors [32].
Men who died from prostate cancer or had stage III or IV at diagnosis were classified as
having advanced prostate cancer. We retrieved information on cancer diagnosis (including
cancers that were prevalent in AGES) and mortality through December 31, 2009 (first
diagnosis was made in 1981). Because of computerized national roster that includes a
unique identification number for each person, follow-up is virtually complete [33].
Statistical Analyses
We used logistic regression models to calculate odds ratios (ORs) and 95% confidence
intervals (CIs) of advanced, localized and total prostate cancer. We compared men who were
high (daily or more) and low (less than daily) consumers of rye bread in early life and
midlife. We created the cut-point based on extreme intake of rye bread in early life, while
retaining proportions sufficient for meaningful analysis. Low intake groups in early life (less
than daily) represented 53.7% of the participants (only 1.1% men never consumed rye
bread) while the high intake group (daily or more) represented 46.3% of the participants
(only 2.7% men consumed rye bread more than once a day). We also divided rye intake into
three groups and explored the association with advanced prostate cancer risk: two times per
week or less (reference group, 15.3% of participants), 3-6 times per week (38.4% of
participants) and daily or more (46.3%). We then employed a trend analysis using these
three groups as a continuous variable.
We considered potential confounders and adjusted in multivariate models for birth year
(continuous), age at study entry in midlife (continuous), as well as: height (continuous),
BMI (≥30, <30 kg/m2), type 2 diabetes in midlife, education (three categories: elementary or
secondary school; college education; university education), family history of prostate
disease, and seeing a physician regularly (model two). In a third model, we further adjusted
for total fish consumption (in three categories: 2.0 portions or less per week, 2.1 – 4.0
portions per week, and 4.1 portions or more per week), salted or smoked fish (once per week
or more vs. 3 times per month or less) fish oil consumption (never vs. once a week or more);
meat consumption (up to 4 times per week vs. 5 times per week or more), and milk intake
(daily or more vs. less than daily). Fruit and vegetable intake as well as physical activity
were excluded from the models since they did not affect the estimates for any of the whole-
grain examined.
Similarly, in the analysis for oatmeal consumption we contrasted cancer odds among
frequent consumers (5 per week) compared with less frequent (≤4 per week) in early life and
midlife. Low intake groups (≤4 per week) included 61.5% of the participants (with 13.3%
who never consumed oatmeal) while the high intake group (5+ per week) represented 38.5%
of the participants (only 0.5% men consumed oatmeal more than once a day). Models were
adjusted as was done in the rye bread analysis, however based on our findings for rye bread
we also adjusted for rye bread intake (daily or more vs. less than daily) in the third model.
Finally, we also analysed the intake of whole-wheat bread in midlife and contrasted cancer
odds among high (daily or more) and low (less than daily) intake. The high intake group
represented 48% of the participants. We used the same covariates in the multivariate
analysis as was done for the oatmeal in the third model.
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For current intake of whole-grain we used proportional hazard regression models to
calculate hazard ratios (HRs) for advanced and total prostate cancer, since prevalent cases
were excluded.
Lastly, the rye bread consumption in midlife and adolescence was pooled in one variable
with four categories to assess potential effects of longitudinal rye bread consumption on
prostate cancer risk. Adjustments were made for same factors as described in the third
model.
In a sensitivity analysis we used logistic regression models to calculate ORs and 95% CIs of
prostate cancer for rye- and oatmeal consumption in early life for incident cases only,
adjusting for the same covariates as was done in the third model. Furthermore, for the
estimates that were statistically significant in the models we also provided confidence
intervals for odds ratios derived by bootstrapping using 200 samples.[34]
For all statistical analyses we used PASW software, version 18.0 (SPSS Inc., 2009, IBM
Chicago, IL, www.spss.com) and STATA version 11 (StataCorp. 2009. Stata Statistical
Software: Release 11. College Station, TX: StataCorp LP ). The study protocol was
approved by the Icelandic Ethical Review Board (VSNb2007120014/03-7) and the Icelandic
Data Protection Authority.
RESULTS
The mean age (SD) was 46.8 years (6.9) when the participants entered the Reykjavik Study
and 76.6 years (5.3) when they entered the AGES-Reykjavik component and provided the
dietary information. The mean follow-up time (SD) for our participants was 34.3 years (6.4).
Table 1 shows characteristics, mostly collected in midlife in the Reykjavik Study, of the
men who reported their dietary habits in the study (n = 2,268) by categories of rye bread-
and oatmeal consumption in early- and midlife. Compared with those who did not consume
rye bread on a daily basis, the high rye bread group was more likely to have lived in a rural
area in early life (33% vs. 21%, respectively). Similarly, high vs. low oatmeal consumption
was correlated with rural residency in early life (37% vs. 21%, respectively). High oatmeal
consumption both in early life and midlife was associated with lower obesity. Otherwise the
groups were similar.
Among the 347 prostate cancer cases who reported their dietary habits, 214 were diagnosed
before and 133 after completing the FFQ. Information on stage at diagnosis was available
for 259 (75%) individuals, and 63 had advanced prostate cancer defined as locally advanced
or metastatic at diagnosis or prostate cancer death. The mean age (SD) at cancer diagnosis
was 74.9 years (6.5).
Whole-grain intake
Men who consumed rye bread daily in adolescence were at decreased risk of prostate cancer
overall (OR = 0.76, 95% CI: 0.59-0.98), and more pronounced decrease for advanced cancer
(OR = 0.47, 95% CI: 0.27-0.84) compared with those consuming rye bread less than daily
(Table 2). When milk intake in adolescence was not included in the model the association
between early life rye bread consumption and advanced prostate cancer was marginally
significant (OR = 0.57, 95% CI: 0.32-1.00). We examined further the association between
rye bread consumption in early life and advanced prostate cancer within the high milk
group, which yielded an odds ratio of 0.50 (95% CI: 0.28-0.91).
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When adding early life residency to the multivariate model, the risk estimate for rye bread
consumption remained the same for advanced prostate cancer (OR = 0.48, 95% CI:
0.26-0.88). We further divided rye intake into three groups and explored the association with
advanced prostate cancer risk. We found a significant trend with risk estimates of 3-6 times
per week (OR = 0.77, 95% CI: 0.35-1.66), and daily or more (OR = 0.39, 95% CI:
0.17-0.87) compared with two times per week or less (Ptrend = 0.009). In contrast to early
life intake, we found no association between daily consumption of rye bread in midlife with
risk of prostate cancer overall nor for advanced prostate cancer. With prevalent prostate
cancer cases excluded, we further explored the association between current daily rye bread
intake and prostate cancer incidence yielding no statistically significant associations; HR =
0.69 (95% CI: 0.45-1.06) for total prostate cancer (n = 133) and HR = 0.64 (95% CI:
0.25-1.61) for advanced prostate cancer (n = 27).
Table 3 presents ORs and 95% CIs of advanced, localized and total prostate cancer by
oatmeal consumption in adolescence and midlife. High intake of oatmeal in adolescence (≥5
vs. ≤4 times/ week) was not associated with risk of prostate cancer diagnosis (OR = 0.99,
95% CI: 0.77-1.27), nor statistically significant with advanced prostate cancer (OR = 0.67,
95% CI: 0.37-1.20). High intake of oatmeal in midlife was not associated with prostate
cancer risk and neither was current intake for either total prostate cancer (HR = 1.06, 95%
CI: 0.74-1.52) nor advanced disease (HR = 0.99, 95% CI: 0.44-2.23). Similarly, we found
no association between intake of whole-wheat bread in midlife, which was only reported for
midlife and current time, and risk of total prostate cancer (OR = 0.92, 95% CI: 0.71-1.18)
nor with advanced prostate cancer (OR = 0.74, 95% CI 0.42-1.30). Similar results were
obtained for current daily intake of whole-wheat bread for total prostate cancer (HR = 1.07,
95% CI: 0.75-1.53) and advanced disease (HR = 0.96, 95% CI: 0.43-2.14).
Table 4 presents ORs and 95% CIs of total prostate cancer and advanced prostate cancer by
consumption of rye bread both in adolescence and midlife. Compared to low rye bread
intake in both life periods, the risk estimates were very similar for high intake in
adolescence, irrespective of consumption pattern in midlife, which suggests that the
reduction of prostate cancer risk is mainly driven by early life consumption.
Sensitivity analysis
To address potential recall bias or differential survival, we performed a sensitivity analysis
limited to men who reported early life whole-grain consumption. Number of incident
prostate cancer in that group was132 and only 27 were diagnosed with advanced disease.
Compared with men consuming rye bread less than once per day, the OR in the multivariate
model for total prostate cancer was 0.82 (95% CI: 0.56-1.20) and 0.73 (95% CI: 0.32-1.68)
for advanced disease among men with high rye bread consumption in adolescence. Men
consuming oatmeal more than five times per week, had an OR of 0.80 (95% CI: 0.54-1.19)
for total prostate cancer and 0.93 (95% CI: 0.40-2.19) for advanced disease compared with
men with low oatmeal consumption (≤4 times/ week) in adolescence. We also performed
sensitivity analysis using a bootstrap approach which largely confirmed our main findings
(table 2).
DISCUSSION
In this population-based cohort of Icelandic men, we found that frequent rye bread
consumption during adolescence was associated with a decreased risk of prostate cancer and
particularly prostate specific mortality or being diagnosed with late stage prostate cancer. In
contrast, frequent oatmeal consumption in adolescence was not associated with prostate
cancer risk nor was mid- or late life consumption for either rye bread or oatmeal. These
findings highlight the potential role of early life diet for prostate cancer risk and are in
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accordance with our previous findings showing that high milk intake in early life, but not in
midlife, is a risk factor for advanced prostate cancer [22]. In fact, early life residency in rural
area, representing high milk and rye bread consumption, was associated with prostate cancer
risk, indicating confounding effect by milk consumption. The association between early life
rye consumption and prostate cancer risk was thus more evident after adjusting for early life
milk consumption and the estimates did not change when we additionally adjusted for early
life residency. Our findings on the importance of early life environment also agree with
evidence from migrant studies showing that it takes at least one generation to gain prostate
cancer risk of the host country [35,2]. A study from Sweden found that immigrants entering
the country in their twenties retain prostate cancer incidence rates similar to those in their
native country [36]. Our findings on midlife consumption are in line with result from a
Danish study on whole-grain intake showing no significant association [16].
Studying early life exposures is a challenge but also imperative for understanding many
chronic diseases that may originate in early life. An important strength of this study is the
extensive background data allowing control for several potential confounding factors.
Further, record linkage to the cancer- and mortality registers permitted complete follow-up
for prostate cancer diagnosis and deaths. However, we cannot exclude the possibility that
unmeasured confounders obscure our observations or that our findings are due to chance.
Moreover, our study is particularly vulnerable to recall bias. Men with prevalent prostate
cancer may evaluate their past dietary consumption differently from men without prostate
cancer. However, our findings indicate that only rye bread in early life, not midlife, is
associated with advanced prostate cancer (not localized prostate cancer) which argues
against differential recall of past rye intake between men with and without prostate cancer.
Furthermore, the hypothesis that rye might be beneficial for health is not well known in the
general Icelandic population. Finally, our sensitivity analysis limited to incident cases,
although with less statistical power, also suggests lower risk of prostate cancer by high rye
bread consumption in early life and our bootstrap analysis suggests similar results.
Non-differential misclassification could also be of concern here; participants have to recall
their dietary habits many decades back in time. Indeed a previous validation study of the
AGES FFQ midlife dietary habits, the retrospective assessment of midlife rye bread
consumption did not correlate with dietary data gathered from the same individuals 18-19
years previously (n = 174) [27]. We have no data on the validity of adolescence dietary
assessment. This would however typically lead to underestimation of the observed
associations and even failure to observe true associations, for example a potential
association between oatmeal consumption in early life as well as midlife rye bread
consumption and advance prostate cancer. Nevertheless, a previous US-based study
indicated that food related memory from childhood over four decades later can be as
accurate as from current diet, especially for food items eaten rarely or daily [37]. Yet,
another limitation to our study is the lack of information about total energy intake and fat
intake; however we adjusted for body mass index measured in midlife, which correlates with
fat- and total energy intake. In conclusion, we still remain cautious when interpreting the
observed association between rye bread consumption in early life and risk of advanced
prostate cancer. The association between consumption of whole grain products at different
stages of life and prostate cancer risk should be further studied in cohorts with more
advanced prostate cancer cases as some of the estimates suggest a decreased risk.
Potential mechanisms that could mediate the effect of rye bread consumption on reduced
prostate cancer risk have not been sufficiently explored. In animal models, rye bran has
especially protective properties against prostate cancer [17-19], most likely because of its
high lignans content compared with oatmeal and wheat [4]. Since there are few human
studies available on rye consumption and prostate cancer risk our attention has been drawn
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to studies on lignans consumption or serum level of enterolactone, a metabolite of lignans. A
small case-control study (83 cases vs. 103 controls) did not find an association between
consumption of lignan precursors (such as flaxseed, dark bread, broccoli, coffee and tea) and
prostate cancer risk [38]. However a case-control study (433 cases vs. 538 controls) in the
United States found an inverse association between high intake of lignans and prostate
cancer [39]. Both studies assessed the diet 1-2 years prior to diagnosis and they did not
distinguish between localized and advanced disease. One case-control study has found high
serum levels of enterolactone to decrease prostate cancer risk [40]. While two nested case-
control studies and one prospective study have not observed an association between
enterolactone and prostate cancer [41-43].
While a prospective study on whole grain rye consumption among men in their fifties did
not observe association with prostate cancer risk [16], some evidence indicates late effect of
rye bran on prostate cancer progression. A pilot intervention study found a reduced plasma
prostate-specific antigen (PSA) among patients with prostate cancer consuming rye whole
grain and bran compared with patients consuming refined wheat products [20] and another
pilot study suggests that rye bran bread can increase apoptosis in prostate tumors [21].
To date no study has addressed early life effect of rye intake on prostate cancer risk. Prostate
tissue contains both estrogen α and β receptors (ERα and ERβ) [44] and the steroid
hormone 17β-estradiol mediates cell growth, proliferation, and differentiation through these
two intracellular receptors [45]. Enterolactone binds to ERα and also somewhat to ERβ, and
can potentially disrupt the effect of 17β-estradiol to some extent and thereby prevent or
reduce estrogen-dependent tumor growth [46]. Conversely, because rye is also a source of
fiber the mechanism of butyrate production may be involved. Butyrate production in the gut
increases with high consumption of fiber from cereals due to fermentation [47], and butyrate
has been shown to inhibit cell growth, and promote cell differentiation and apoptosis in
prostate cancer cells [5]. Furthermore, fiber may reduce reabsorption of estrogen in the
bowel [48]. Alternatively, rye has been suggested to have positive effects on long-term
insulin secretion [6,7], which could be important since prostate cancer has been associated
with insulin resistance [8-10]. Insulin is indeed a growth factor for many tumors and
hyperinsulinemia results in increased availability of insulin-like growth factor-1 (IGF-1)
[49], a potential risk factor for prostate cancer [50]. Thus intake of rye may affect several
pathways relevant for carcinogenesis in the prostate. The fact that we did not get the same
results for oatmeal consumption possibly strengthens the hypothesis between lignans and
prostate cancer, because oatmeal contains only half the amount of total lignans compared
with rye, and contains also different types of lignans [4]. Possibly a combination of lignans
and fiber from rye affects different mechanisms and should be studied further, especially for
early life period.
In summary, our data suggest that rye bread consumption in adolescence is associated with
decreased risk of advanced prostate cancer later in life. Our findings call for further studies
on potential mechanisms for the early life-dependent impact of rye and other food items on
the risk of advanced prostate cancer.
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Table 1
Characteristics of male participants by their rye bread- and oatmeal consumption
All Rye bread intake in
adolescence
Oatmeal intake in
adolescence
Rye bread intake in
midlife
Oatmeal intake in
midlife
N= 2,268 High
a, n=
1,046
Lowb, n=
1,212
Highc, n=
869
Lowd, n=
1,386
Higha, n=
678
Lowb, n=
1,582
Highc, n=
572
Lowd, n=
1,687
n (%) n (%) n (%) n (%) n (%) n (%) n (%) n (%) n (%)
Age at entry to the
AGES-Reykjavik
-mean age (SD) 76.6 (5.3) 77.9 (5.5) 75.4 (4.9) 77.6 (5.5) 75.9 (5.1) 78.2 (5.7) 75.8 (5.0) 78.2 (5.8) 76.2 (5.2)
Education
 -Primary and Secondary 1663 (73.3) 763 (72.9) 896 (73.9) 623 (71.7) 1032 (74.5) 504 (74.3) 1155 (73.0) 400 (69.9) 1260 (74.7)
 -College 314 (13.8) 146 (14.0) 165 (13.6) 125 (14.4) 185 (13.3) 90 (13.3) 222 (14.0) 84 (14.7) 226 (13.4)
 -University 291 (12.8) 137 (13.1) 151 (12.5) 121 (13.9) 169 (12.2) 84 (12.4) 205 (13.0) 88 (15.4) 201 (11.9)
Prostate disease in the
family 224 ( 9.9) 113 (10.8) 111 ( 9.2) 99 (11.4) 123 ( 8.9) 68 (10.0) 156 ( 9.9) 59 (10.3) 164 ( 9.7)
Regular health check-up 421 (18.6) 189 (18.1) 229 (18.9) 154 (17.7) 263 (19.0) 120 (17.7) 297 (18.8) 113 (19.8) 301 (17.8)
Diabetes type 2 in
midlife 38 ( 1.7) 18 ( 1.7) 20 ( 1.7) 17 ( 2.0) 21 ( 1.5) 13 ( 1.9) 25 ( 1.6) 10 ( 1.7) 28 ( 1.7)
Smoking status in
midlife
 -Never 575 (25.4) 276 (26.4) 295 (24.3) 251 (28.9) 323 (23.3) 181 (26.7) 390 (24.7) 172 (30.1) 401 (23.8)
 -Previously 529 (23.3) 274 (26.2) 253 (20.9) 202 (23.2) 321 (23.2) 165 (24.3) 363 (22.9) 154 (26.9) 374 (22.2)
 -Current 1164 (51.3) 496 (47.4) 664 (54.8) 416 (47.9) 742 (53.5) 332 (49.0) 829 (52.4) 246 (43.0) 912 (54.1)
Early life residency e
 -Reykjavik 816 (36.9) 336 (32.9) 477 (40.4) 214 (25.6) 594 (43.6) 221(33.5) 592 (38.3) 179 (32.3) 633 (38.4)
 -Sea village 724 (32.7) 309 (30.2) 414 (35.1) 281 (33.6) 443 (32.5) 210 (31.9) 514 (33.2) 177 (31.9) 547 (33.2)
 -Rural area 599 (27.1) 341 (33.4) 253 (21.4) 310 (37.0) 286 (21.0) 203 (30.8) 392 (25.4) 184 (33.2) 411 (24.9)
 -Combination of rural
area / sea village 74 ( 3.3) 37 ( 3.6) 36 ( 3.1) 32 ( 3.8) 40 ( 2.9) 25 ( 3.8) 48 ( 3.1) 14 ( 2.5) 59 ( 3.6)
BMI ≥ 30 in midlife 163 ( 7.2) 84 ( 8.0) 79 ( 6.5) 44 ( 5.1) 172 ( 9.1) 47 ( 7.0) 116 ( 7.3) 28 ( 4.9) 135 ( 8.0)
Mean BMI (m/kg2) in
midlife (SD) 25.5 (3.1) 25.6 (3.1) 25.4 (3.1) 25.3 (3.0) 25.6 (3.2) 25.6 (3.1) 25.4 (3.1) 25.2 (3.0) 25.6 (3.2)
Mean height (cm) in
midlife (SD) 177.9 (6.0) 177.7 (6.0) 178.1 (6.0) 177.5 (5.9) 178.2 (6.1) 177.7 (6.1) 178.0 (6.0) 177.8 (6.1) 178.0 (6.0)
High intake of other
food groups f
 -Milk and milk
products (daily or more ) 1804 (79.5) 935 (89.4) 863 (71.2) 760 (87.5) 1031 (74.5) 512 (75.5) 909 (57.8) 431 (75.6) 991 (58.8)
 -Fish (> 4 portions per
week ) 868 (38.3) 460 (44.0) 404 (33.4) 407 (46.9) 457 (33.0) 256 (37.8) 423 (26.8) 240 (42.0) 440 (26.1)
 -Fish liver oil (≥ 1 per
week ) 1461 (64.4) 657 (63.0) 797 (66.0) 599 (69.2) 857 (62.0) 502 (74.3) 1168 (74.1) 468 (82.1) 1202 (71.4)
 -Meat (≥ 5 per week ) 114 ( 5.0) 58 ( 5.6) 55 ( 4.5) 42 ( 4.9) 70 ( 5.1) 84 (12.4) 144 ( 9.1) 72 (12.6) 156 ( 9.3)
 - Fruits (daily or more ) 21 ( 0.9) 16 ( 1.5) 5 ( 0.4) 6 ( 0.7) 15 ( 1.1) 35 ( 5.2) 67 ( 4.2) 42 ( 7.5) 60 ( 3.6)
 - Vegetables (daily or
more ) 35 ( 1.5) 27 ( 2.6) 7 ( 0.7) 20 ( 2.3) 15 ( 1.1) 55 ( 8.1) 59 ( 3.7) 52 ( 9.1) 62 ( 3.7)
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Abbreviations: BMI, body mass index; cm, centimeters; kg, kilogram; m, meter; SD, standard deviation
aConsuming rye bread daily
bConsuming rye bread less than daily
cConsuming oatmeal five times per week or more
dConsuming oatmeal four times per week or less
e
Data on residency is missing for 55 men
fAt the same time (adolescence/midlife) when rye bread and otamel consumption was high or low. High consumption in adolsecence is shown for
all particpants (n=2,268)
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Table 2
Prostate cancer by rye bread intake in early- and midlife
Adolescence (14-19 years of age) Age adjusted OR(95% CI) ORa (95% CI) ORb (95% CI)
Advanced (n= 62) Non-PCa (n) PCa (n)
n = 1,978
Low intake 1,025 35 1.00 1.00 1.00
High intake 891 27 0.68 (0.40-1.15) 0.68 (0.39-1.16) 0.47 (0.27-0.84)*
Localized (n=280) Non-PCa (n) PCa (n)
n = 2,196
Low intake 1,025 152 1.00 1.00 1.00
High intake 891 128 0.89 (0.68-1.15) 0.87 (0.67-1.14) 0.83 (0.63-1.09)
Total (n=342) Non-PCa (n) PCa (n)
n = 2,258
Low intake 1,025 187 1.00 1.00 1.00
High intake 891 155 0.84 (0.66-1.07) 0.84 (0.66-1.07) 0.76 (0.59-0.98)**
Midlife (40-50 years of age) Age adjusted OR(95% CI) ORa (95% CI) ORb (95% CI)
Advanced (n= 63) Non-PCa (n) PCa (n)
n = 1,977
Low intake 1,338 42 1.00 1.00 1.00
High intake 576 21 0.93 (0.54-1.62) 0.96 (0.55-1.67) 0.87 (0.49-1.54)
Localized (n=283) Non-PCa (n) PCa (n)
n = 2,197
Low intake 1,338 202 1.00 1.00 1.00
High intake 576 81 0.85 (0.64-1.13) 0.84 (0.63-1.13) 0.84 (0.63-1.13)
Total (n=346) Non-PCa (n) PCa (n)
n = 2,260
Low intake 1,338 244 1.00 1.00 1.00
High intake 576 102 0.87 (0.67-1.13) 0.87 (0.67-1.12) 0.85 (0.65-1.12)
Abbreviations: CI, confidence interval; OR, odds ratio
adjustment made for birth year, age at study entry in midlife, education, family history of prostate disease, going to a physician regularly, height in
midlife, BMI in midlife, and type 2 diabetes in midlife
bAdditional adjustments made for fish-, fish liver oil-, meat-, and milk intake
*
Bootstrap OR and 95% CI for advanced prostate cancer: 0.47 (0.27-0.81)
**
Bootstrap OR and 95% CI for total prostate cancer: 0.76 (0.60-0.97)
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Table 3
Prostate cancer by oatmeal intake in early- and midlife
Adolescence (14-19 years of age) Age adjusted OR(95% CI) ORa (95% CI) ORb (95% CI)
Advanced (n= 60) Non-PCa (n) PCa (n)
n = 1,973
Low intake 1,183 39 1.00 1.00 1.00
High intake 730 21 0.73 (0.42-1.27) 0.71 (0.40-1.24) 0.67 (0.37-1.20)
Localized (n=282) Non-PCa (n) PCa (n)
n = 2,195
Low intake 1,183 164 1.00 1.00 1.00
High intake 730 118 1.11 (0.86-1.44) 1.07 (0.82-1.39) 1.02 (0.82-1.42)
Total (n=342) Non-PCa (n) PCa (n)
n = 2,255
Low intake 1,183 203 1.00 1.00 1.00
High intake 730 139 1.03 (0.81-1.31) 0.99 (0.78-1.26) 0.99 (0.77-1.27)
Midlife (40-50 years of age) Age adjusted OR(95% CI) ORa (95% CI) ORb (95% CI)
Advanced (n= 63) Non-PCa (n) PCa (n)
n = 1,979
Low intake 1,441 41 1.00 1.00 1.00
High intake 475 22 1.45 (0.85-2.48) 1.37 (0.79-2.37) 1.33 (0.75-2.38)
Localized (n=280) Non-PCa (n) PCa (n)
n = 2,196
Low intake 1,441 205 1.00 1.00 1.00
High intake 475 75 1.06 (0.80-1.41) 1.01 (0.76-1.35) 1.05 (0.78-1.43)
Total (n=343) Non-PCa (n) PCa (n)
n = 2,259
Low intake 1,441 246 1.00 1.00 1.00
High intake 475 97 1.12 (0.87-1.46) 1.07 (0.82-1.39) 1.10 (0.83-1.44)
Abbreviations: CI, confidence interval; OR, odds ratio
aAdjustment made for birth year, age at study entry in midlife, education, family history of prostate disease, going to a physician regularly, height
in midlife, BMI in midlife, and type 2 diabetes in midlife
bAdditional adjustments made for fish-, fish liver oil-, meat-, and milk intake
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Table 4
Prostate cancer by longitudinal rye bread intake
Total prostate cancer (n= 338)
Adolescence Midlife Number ORa (95%CI)
Lowb Low 1083 1.00
Low Highc 123 0.82 (0.47-1.43)
High Low 491 0.75 (0.55-1.03)
High High 554 0.74 (0.54-1.00)
Advanced prostate cancer (n =59)
Adolescence Midlife Number ORa (95%CI)
Low Low 942 1.00
Low High 112 1.36 (0.50-3.72)
High Low 432 0.44 (0.21-0.96)
High High 485 0.53 (0.27-1.06)
aAdjustment made for birth year, age at study entry in midlife, education, family history of prostate disease, going to a physician regularly, height
in midlife, BMI in midlife, and type 2 diabetes in midlife, fish-, fish liver oil-, meat-, and milk intake in adolescence
bConsuming rye bread less than daily
cConsuming rye bread daily or more
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